

Gino K In

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5774702/publications.pdf>

Version: 2024-02-01

21
papers

342
citations

1040056

9
h-index

839539

18
g-index

22
all docs

22
docs citations

22
times ranked

540
citing authors

#	ARTICLE	IF	CITATIONS
1	Disparities in nonmelanoma skin cancer in Hispanic/Latino patients based on Mohs micrographic surgery defect size: A multicenter retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 353-358.	1.2	13
2	Transcriptional Profiling of Malignant Melanoma Reveals Novel and Potentially Targetable Gene Fusions. <i>Cancers</i> , 2022, 14, 1505.	3.7	1
3	Factors Associated With Hospitalization Among Breast Cancer Patients With COVID-19: A Diverse Multi-Center Los Angeles Cohort Study. <i>Clinical Breast Cancer</i> , 2022, 22, e558-e566.	2.4	4
4	Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma. , 2022, 10, e004839.		4
5	Abstract 50: Multi-omics and immune cell profiling of metastatic uveal melanomas. <i>Cancer Research</i> , 2022, 82, 50-50.	0.9	0
6	PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1803-1811.	2.5	24
7	18F-FDG PET/CT Monitoring of Response to Programmed Death Protein 1 Blockade in Metastatic Basal Cell Carcinoma. <i>Clinical Nuclear Medicine</i> , 2021, Publish Ahead of Print, e436-e437.	1.3	2
8	COVID-19 Outcomes of Patients With Differentiated Thyroid Cancer: A Multicenter Los Angeles Cohort Study. <i>Endocrine Practice</i> , 2021, 27, 90-94.	2.1	10
9	The Importance of Understanding the Stages of COVID-19 in Treatment and Trials. <i>AIDS Reviews</i> , 2021, 23, 40-47.	1.0	66
10	The time to offer treatments for COVID-19. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 505-518.	4.1	20
11	Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922). <i>Melanoma Research</i> , 2021, 31, 162-172.	1.2	6
12	Examining low rates of dermatology visits in solid organ transplant recipients. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	1.2	0
13	Characterizing DNA methylation signatures and their potential functional roles in Merkel cell carcinoma. <i>Genome Medicine</i> , 2021, 13, 130.	8.2	12
14	Acral lentiginous melanomaâ€™Population, treatment, and survival using the NCDB from 2004 to 2015. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 1049-1061.	3.3	8
15	Impact of COVID-19 infection among cancer patients treated at the Los Angeles County Medical Center. <i>Cancer Treatment and Research Communications</i> , 2021, 26, 100273.	1.7	7
16	Skin cancer and dermatoses in a majority-Hispanic population of solid organ transplant recipients. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 607-610.	1.2	2
17	Concurrent radiation therapy with programmed cell death protein 1 inhibition leads to a complete response in advanced cutaneous squamous cell carcinoma. <i>JAAD Case Reports</i> , 2019, 5, 763-766.	0.8	12
18	Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance. <i>Nature Communications</i> , 2019, 10, 1693.	12.8	119

#	ARTICLE	IF	CITATIONS
19	Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma: A Retrospective Analysis From a Single Tertiary Academic Medical Center. <i>Dermatologic Surgery</i> , 2019, 45, 254-267.	0.8	21
20	Development of metastatic brain disease involves progression through lung metastases in <i>EGFR</i> mutated non-small cell lung cancer. <i>Convergent Science Physical Oncology</i> , 2017, 3, 035002.	2.6	5
21	Development of metastatic brain disease involves progression through lung metastases in mutated non-small cell lung cancer. <i>Convergent Science Physical Oncology</i> , 2017, 3, .	2.6	3